Ministry of Health analyzes vaccine acquisition process to define smallpox immunization strategy

Ministry of Health analyzes vaccine acquisition process to define smallpox immunization strategy

With the threat of smallpox spread, the Minister of Health already evaluates the acquisition process vaccines, to then define an immunization strategy in Brazil. There is no stock of the immunizer in the country as the disease was eradicated in the 1970s.

Because there is no vaccine to protect against monkeypox, the World Health OrganizationWHO) recommends an immunizing agent that works against traditional smallpox (smallpox), as long as it is more current, second- or third-generationwhich is not replicated in the human body). This type of drug has been shown to be 85% effective against monkeypox, the organization said.

There is a vaccine in use in some countries that is already highly valued. It is called Jynneos (in the United States), Imvamune (in Canada) or Imvanex (in Europe) and is manufactured by the Danish laboratory Bavarian Nordic. The immunizer was approved in 2019 by the US Food and Drug Administration (FDA) and in 2013 by the European Medicines Agency (EMEA).

In Brazil, however, the product has not yet received a registration application from the National Health Surveillance Agency (warn).

Each new drug or vaccine, before being released for use in the country, needs authorization from the National Health Surveillance Agency (warn). Although this is the usual procedure, the Agency has reported that there are currently no applications for vaccines or medications for monkeypox in Brazil. The initiative must come from pharmaceutical laboratories.

Jynneos is unable to replicate in the human body, is less likely to cause side effects than conventional vaccines, and has been shown to be effective in inducing a potent immune response. Those who have not been previously vaccinated against smallpox should receive two doses, 28 days apart. But the duration of the protection is still unclear.

Despite being cited, the vaccine is not widely available. Faced with growing cases of monkeypox in the world, Bavarian Nordic has announced that it has increased immunizer production. The Ministry of Health, however, did not say which vaccine is being tested for purchase.

This week, the Secretary of Health Surveillance of the Ministry of Health, Arnaldo de Medeiros, reported that the federal government is negotiating the purchase of an immunizer that protects against smallpox, but did not give further details. The statement was made in an interview on the portal metropolis.

According to Medeiros, a meeting has even been held with the manufacturing company, and the acquisition is mediated by the Pan American Health Organization (PAHO). The expectation, he said, is that the doses will reach the country between the third and fourth quarters of this year.

Who can be vaccinated

The World Health Organization (WHO) does not recommend mass vaccination of the population against monkeypox. According to the organization, only priority groups should receive the immune agent, such as laboratory workers exposed to the virus and people who have had close contact with infected people.

Also according to the WHO, measures to control and diagnose the disease, in addition to vaccinating specific groups, can prevent a global outbreak.

What are the symptoms of monkeypox?

Symptoms are similar, to a lesser extent, to those seen in smallpox patients: fever, headache, muscle aches, and back pain for the first five days. Then there are rashes – on the face, palms and soles of the feet -, injuries, pustules and finally scabs.

How is it transmitted?

The infection in the first cases is due to direct contact with blood, body fluids, skin lesions or mucous membranes of infected animals. Secondary person-to-person transmission may be the result of close contact with infected airway secretions, skin lesions of an infected person, or objects recently contaminated with biological fluids or materials from a patient’s wounds.

health risk

According to experts, the smallpox of the monkey should not be the same size as the covid-19. According to scientist Ester Sabino, a professor at the University of São Paulo (USP) and leader of the group responsible for the first sequencing of the virus in Brazil, this virus that causes smallpox in monkeys has no airborne transmission, as does the coronavirus. .

– Monkeypox needs very close contact for people to become infected. Therefore, the smallpox of the monkey will probably not be the same size as the Covid, “he said in a statement. interview with the newspaper O Estado de S. Paulo.

confirmed cases in Brazil

Brazil currently has five confirmed cases, three in São Paulo, one in Rio Grande do Sul and one in Rio de Janeiro. Eight cases are still being investigated. There was an investigated death in Minas Gerais, but the Ezequiel Dias Foundation has ruled it out this Wednesday (15) for smallpox. He is a 41-year-old man with no travel history and no contact with a suspected or confirmed case of the disease. The causes of death are still being investigated.


Leave a Comment

Your email address will not be published.